These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37258648)

  • 1. The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?
    Benjamin DJ; Lythgoe MP
    Nat Rev Clin Oncol; 2023 Sep; 20(9):577-578. PubMed ID: 37258648
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
    Sasinowski FJ; Varond AJ
    Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues.
    Miller HI
    Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
    Purpura CA; Garry EM; Honig N; Case A; Rassen JA
    Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
    Beakes-Read G; Neisser M; Frey P; Guarducci M
    Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending the US Food and Drug Administration's Postmarket Authorities.
    Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
    JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA's definitions, designations, and drug approvals: too daring?
    The Lancet Haematology
    Lancet Haematol; 2018 Aug; 5(8):e321. PubMed ID: 30075830
    [No Abstract]   [Full Text] [Related]  

  • 10. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 11. Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence.
    Hey SP; Feldman WB; Jung EH; D'Andrea E; Kesselheim AS
    J Law Med Ethics; 2019 Sep; 47(3):381-387. PubMed ID: 31560631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT; Duhamel LM; Dievler A; Price R
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated Approval - Taking the FDA's Concerns Seriously.
    Sachs RE; Donohue JM; Dusetzina SB
    N Engl J Med; 2022 Jul; 387(3):199-201. PubMed ID: 35793197
    [No Abstract]   [Full Text] [Related]  

  • 14. Great Trees Require Strong Roots: Evaluating Data and Delegation Doctrine Underlying Proposed Reforms to FDA's Accelerated Approval Program.
    Deshmukh AD
    J Law Med Ethics; 2023; 51(4):920-925. PubMed ID: 38477271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global consequences of the US FDA's accelerated approval of cancer drugs.
    Akhade A; Sirohi B; Gyawali B
    Lancet Oncol; 2022 Feb; 23(2):201-203. PubMed ID: 35114117
    [No Abstract]   [Full Text] [Related]  

  • 16. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 17. The latest drugs on the FDA's radar.
    Waldron T
    Behav Healthc; 2006 Jun; 26(6):34-5. PubMed ID: 16833213
    [No Abstract]   [Full Text] [Related]  

  • 18. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential policy reforms to strengthen the accelerated approval pathway.
    Kaltenboeck A; Mehlman A; Pearson SD
    J Comp Eff Res; 2021 Nov; 10(16):1177-1186. PubMed ID: 34427103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM
    Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.